[Preliminary results with a new oral antidiabetic drug of the sulfanylurea series: glibenclamide or HB 419].
D000293:Adolescent; D000328:Adult; D000368:Aged; D003510:Cyclohexanes / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D013450:Sulfones / Q000627:therapeutic use; D014044:Tolbutamide / Q000627:therapeutic use; D014508:Urea / Q000627:therapeutic use*
D003510:Cyclohexanes; D007004:Hypoglycemic Agents; D013450:Sulfones; D014508:Urea; D014044:Tolbutamide
Primi risultati terapeutici con un nuovo antidiabetico orale della serie sulfanilureica: la glibenclamide o HB 419.